CTM makes an important point. There's a big difference between a drug trial missing an abstract numerical value in a significance calculation for a Primary End Point, and the *science* behind the drug failing.
Leronlimab's detractors love to hammer on the P-Value of Primary End Points in Leronlimab studies. That's because they have ZERO credible ammunition to train on the science behind what Leronlimab does to the patients in those studies.
Market Data 
Markets 
AI
